Challenges and new opportunities in the investigation of new drug therapies to treat frontotemporal dementia

Edward D. Huey*, Nicole Armstrong, Parastoo Momeni, Jordan Grafman

*Corresponding author for this work

Research output: Contribution to journalReview article

11 Citations (Scopus)

Abstract

Background: Frontotemporal dementia spectrum disorders are a set of neurodegenerative disorders affecting the frontal and anterior temporal lobes. They are often fatal, and currently no medications have been shown to slow their progression. Recent developments in understanding these disorders may aid in developing treatments. Objective: To discuss the development of drug therapies for frontotemporal dementia spectrum disorders, both those under current investigation and those that could be targets for future investigation. Methods: This review is divided into four sections: First, a brief review of frontotemporal dementia spectrum disorders; second, a discussion of the challenges in the development of drug therapies third, a review of the current clinical trials; and finally a discussion of some recent discoveries, which have sparked new areas of investigation. Conclusions: Hopefully, advances in understanding of frontotemporal dementia spectrum disorders and clinical trial design will aid the development of new treatments.

Original languageEnglish (US)
Pages (from-to)1367-1376
Number of pages10
JournalExpert Opinion on Therapeutic Targets
Volume12
Issue number11
DOIs
StatePublished - Nov 1 2008

Fingerprint

Drug therapy
Frontotemporal Dementia
Drug Therapy
Design aids
Clinical Trials
Temporal Lobe
Neurodegenerative Diseases
Therapeutics

Keywords

  • Frontotemporal dementia
  • Medication treatment
  • Neurodegenerative disorders
  • Neuroprotection

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

@article{9b6466ab0fe943e5aceb898461b119ca,
title = "Challenges and new opportunities in the investigation of new drug therapies to treat frontotemporal dementia",
abstract = "Background: Frontotemporal dementia spectrum disorders are a set of neurodegenerative disorders affecting the frontal and anterior temporal lobes. They are often fatal, and currently no medications have been shown to slow their progression. Recent developments in understanding these disorders may aid in developing treatments. Objective: To discuss the development of drug therapies for frontotemporal dementia spectrum disorders, both those under current investigation and those that could be targets for future investigation. Methods: This review is divided into four sections: First, a brief review of frontotemporal dementia spectrum disorders; second, a discussion of the challenges in the development of drug therapies third, a review of the current clinical trials; and finally a discussion of some recent discoveries, which have sparked new areas of investigation. Conclusions: Hopefully, advances in understanding of frontotemporal dementia spectrum disorders and clinical trial design will aid the development of new treatments.",
keywords = "Frontotemporal dementia, Medication treatment, Neurodegenerative disorders, Neuroprotection",
author = "Huey, {Edward D.} and Nicole Armstrong and Parastoo Momeni and Jordan Grafman",
year = "2008",
month = "11",
day = "1",
doi = "10.1517/14728222.12.11.1367",
language = "English (US)",
volume = "12",
pages = "1367--1376",
journal = "Expert Opinion on Therapeutic Targets",
issn = "1472-8222",
publisher = "Informa Healthcare",
number = "11",

}

Challenges and new opportunities in the investigation of new drug therapies to treat frontotemporal dementia. / Huey, Edward D.; Armstrong, Nicole; Momeni, Parastoo; Grafman, Jordan.

In: Expert Opinion on Therapeutic Targets, Vol. 12, No. 11, 01.11.2008, p. 1367-1376.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Challenges and new opportunities in the investigation of new drug therapies to treat frontotemporal dementia

AU - Huey, Edward D.

AU - Armstrong, Nicole

AU - Momeni, Parastoo

AU - Grafman, Jordan

PY - 2008/11/1

Y1 - 2008/11/1

N2 - Background: Frontotemporal dementia spectrum disorders are a set of neurodegenerative disorders affecting the frontal and anterior temporal lobes. They are often fatal, and currently no medications have been shown to slow their progression. Recent developments in understanding these disorders may aid in developing treatments. Objective: To discuss the development of drug therapies for frontotemporal dementia spectrum disorders, both those under current investigation and those that could be targets for future investigation. Methods: This review is divided into four sections: First, a brief review of frontotemporal dementia spectrum disorders; second, a discussion of the challenges in the development of drug therapies third, a review of the current clinical trials; and finally a discussion of some recent discoveries, which have sparked new areas of investigation. Conclusions: Hopefully, advances in understanding of frontotemporal dementia spectrum disorders and clinical trial design will aid the development of new treatments.

AB - Background: Frontotemporal dementia spectrum disorders are a set of neurodegenerative disorders affecting the frontal and anterior temporal lobes. They are often fatal, and currently no medications have been shown to slow their progression. Recent developments in understanding these disorders may aid in developing treatments. Objective: To discuss the development of drug therapies for frontotemporal dementia spectrum disorders, both those under current investigation and those that could be targets for future investigation. Methods: This review is divided into four sections: First, a brief review of frontotemporal dementia spectrum disorders; second, a discussion of the challenges in the development of drug therapies third, a review of the current clinical trials; and finally a discussion of some recent discoveries, which have sparked new areas of investigation. Conclusions: Hopefully, advances in understanding of frontotemporal dementia spectrum disorders and clinical trial design will aid the development of new treatments.

KW - Frontotemporal dementia

KW - Medication treatment

KW - Neurodegenerative disorders

KW - Neuroprotection

UR - http://www.scopus.com/inward/record.url?scp=56249100405&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56249100405&partnerID=8YFLogxK

U2 - 10.1517/14728222.12.11.1367

DO - 10.1517/14728222.12.11.1367

M3 - Review article

VL - 12

SP - 1367

EP - 1376

JO - Expert Opinion on Therapeutic Targets

JF - Expert Opinion on Therapeutic Targets

SN - 1472-8222

IS - 11

ER -